Caris Life Sciences Validates FDA-Approved MI Cancer Seek with Clinical Study

Caris Life Sciences has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek, a FDA-approved assay for solid tumor profiling in both adult and pediatric patients. The study demonstrates that MI Cancer Seek works reliably for detecting multiple variant types of high clinical significance, with positive and negative percent agreement ranging from 97% to 100%. The assay supports eight companion diagnostic (CDx) claims and offers the added benefit of simultaneous RNA and DNA extraction from minimal tissue input. MI Cancer Seek is the first and only test to combine whole exome sequencing (WES) and whole transcriptome sequencing (WTS) with FDA-approved CDx indications for solid tumor profiling.